Loading data for GOSS — first visit, this takes a few seconds.

提醒

Gossamer Bio Inc. (GOSS)

NasdaqGS: GOSS · 即時價格 · USD

0.17

+0.00 (0.00%)

收盤價： Aug 28, 2026, 8:00 PM

0.17

+1.47%

盤後: 7:59 PM

股價、關鍵數字和最新消息，都在這一頁。

0.00% (1D)

無可用資料

買價	0.17
市值	83.15M
營收 (ttm)	53.29M
淨利（ttm）	-125.22M
	2.01
	-0.66
	n/a
	-0.87
P/B (ttm)	-0.89
P/S (ttm)	1.56
財報日期	Nov 4, 2026

賣價	0.17
成交量	7,436,047
20 日平均成交量	28,385,550
開盤價	0.17
前收盤價	0.17
當日區間	0.17 - 0.17
52 週範圍	0.11 - 3.87
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It ha...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Feb 8, 2019

員工 161

證券交易所 NasdaqGS

股票代號 GOSS

網站 https://www.gossamerbio.com

完整的公司簡介

財務表現

Gossamer Bio 在 2025 年的營收為 48.47M，較前一年的 114.7M 減少 -57.74%。淨利為 -170.37M，較前期增加 201.39%。

財務報表

財報驚奇

Gossamer Bio 已於 Aug 13, 2026 公布季度財報：

營收為 $16.95M 低於預期 $0, 年增 71.45% 成長.
每股盈餘為 -0.1 超出預期 0.02, 年增 41.18% 成長.

下次財報發布

Gossamer Bio Inc. 的下次財報預計於 Nov 4, 2026, 盤中。
分析師預估營收 ... 升級

新聞動態

2 天前 · Insider Monkey

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

Gossamer Bio, Inc. (NASDAQ:GOSS) announced a structured private placement on August 21 that could generate up to approximately $250 million in gross proceeds. However, Gossamer Bio, Inc. (NASDAQ:GOSS)...

5 天前 · Pharmaceutical Technology

Gossamer Bio announces $250m in funding to advance seralutinib

The proceeds will help advance seralutinib's clinical development and potential commercialisation.

1 週前 · MT Newswires

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S

1 週前 · InvestorsHub

Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio has structured the financing around key seralutinib regulatory milestones, with $150 million committed and another $100 million potentially available if the pulmonary arterial hypertensio...

1 週前 · MT Newswires

Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell

Gossamer Bio (GOSS) shares were up 10% in Friday's premarket trading after the company said it has a

第 1 頁，共 2 頁

Gossamer Bio Inc. (GOSS)